November 21, 2018
Janssen Biotech Inc. said on Tuesday it was going to sprint to the U.S. Supreme Court after the Federal Circuit refused to block sales of generic versions of Zytiga while Janssen appeals a ruling that invalidated a patent on the blockbuster oncology medication.